Clinical guidelines for the management of depression with specific comorbid psychiatric conditions French recommendations from experts (the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental).
BMC Psychiatry. 2019-01-30; 19(1):
DOI: 10.1186/s12888-019-2025-7
Lire sur PubMed
1. BMC Psychiatry. 2019 Jan 30;19(1):50. doi: 10.1186/s12888-019-2025-7.
Clinical guidelines for the management of depression with specific comorbid
psychiatric conditions French recommendations from experts (the French
Association for Biological Psychiatry and Neuropsychopharmacology and the
fondation FondaMental).
Bennabi D(1), Yrondi A(2), Charpeaud T(3), Genty JB(4), Destouches S(4),
Lancrenon S(4), Allaili N(5), Bellivier F(5), Bougerol T(6), Camus V(7), Doumy
O(8), Dorey JM(9)(10)(11), Haesebaert F(12), Holtzmann J(6), Lançon C(13),
Lefebvre M(12), Moliere F(14), Nieto I(5), Rabu C(15), Richieri R(13), Schmitt
L(2), Stephan F(16), Vaiva G(17), Walter M(16), Leboyer M(15), El-Hage W(7),
Aouizerate B(8), Haffen E(18), Llorca PM(3), Courtet P(14).
Author information:
(1)Service de Psychiatrie clinique, Centre Expert Dépression Résistante
FondaMental, Centre Investigation Clinique 1431-INSERM, EA 481 Neurosciences,
Université de Bourgogne Franche Comté, 25030, Besançon, France.
.
(2)Service de Psychiatrie et de Psychologie Médicale de l’adulte, Centre Expert
Dépression Résistante FondaMental, CHRU de Toulouse, Hospital Purpan, ToNIC,
Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse,
France.
(3)Service de Psychiatrie de l’adulte B, Centre Expert Dépression Résistante
FondaMental, CHU de Clermont-Ferrand, Clermont-Ferrand, France.
(4)SYLIA-STAT, 10, boulevard du Maréchal-Joffre, 92340, Bourg-la-Reine, France.
(5)Service de Psychiatrie adulte, Centre Expert Dépression Résistante
FondaMental, Hôpital Fernand-Widal, Paris, France.
(6)Service de Psychiatrie de l’adulte, CS 10217, Centre Expert Dépression
Résistante FondaMental, CHU de Grenoble, Hôpital Nord, Grenoble, France.
(7)Clinique Psychiatrique Universitaire, Centre Expert Dépression Résistante
FondaMental, CHRU de Tours, Université de Tours, Inserm U1253 imaging and Brain:
iBrain, Tours, France.
(8)Pôle de Psychiatrie Générale et Universitaire, Centre Expert Dépression
Résistante FondaMental, CH Charles Perrens, UMR INRA 1286, NutriNeuro,
Université de Bordeaux, Bordeaux, France.
(9)Old Age Psychiatry Unit, pôle EST, Centre Hospitalier le Vinatier, Bron,
France.
(10)Brain Dynamics and Cognition, Lyon Neuroscience Research Center, INSERM
U1028, CNRS UMR 5292, Lyon, France.
(11)Geriatrics Unit, CM2R, Hospices civils de Lyon, Hôpital des Charpennes,
Villeurbanne, France.
(12)Service universitaire des pathologies psychiatriques résistantes, Centre
expert FondaMental, PSYR2 Team, Lyon Neuroscience Research Center, INSERM U1028,
CNRS UMR5292, Centre Hospitalier Le Vinatier, University Lyon 1, Bron, France.
(13)Pôle Psychiatrie, Centre Expert Dépression Résistante FondaMental, CHU La
Conception, Marseille, France.
(14)Département des Urgences et Post-Urgences Psychiatriques, Centre Expert
Dépression Résistante FondaMental, CHU Montpellier, Univ Montpellier,
Montpellier, France.
(15)DHU PePSY, Pole de psychiatrie et d’addictologie des Hôpitaux Universitaires
Henri Mondor, Université Paris Est Créteil, Créteil, France.
(16)Service hospitalo-universitaire de psychiatrie d’adultes et de psychiatrie
de liaison – secteur 1, Centre Expert Dépression Résistante Fondamental, CHRU
Brest, hôpital de Bohars, Bohars, France.
(17)Service de Psychiatrie adulte, Centre Expert Dépression Résistante
FondaMental, CHU de Lille, Hôpital Fontan 1, Lille, France.
(18)Service de Psychiatrie clinique, Centre Expert Dépression Résistante
FondaMental, Centre Investigation Clinique 1431-INSERM, EA 481 Neurosciences,
Université de Bourgogne Franche Comté, 25030, Besançon, France.
BACKGROUND: Recommendations for pharmacological treatments of major depression
with specific comorbid psychiatric conditions are lacking.
METHOD: The French Association for Biological Psychiatry and
Neuropsychopharmacology and the fondation FondaMental developed expert consensus
guidelines for the management of depression based on the RAND/UCLA
Appropriatneness Method. Recommendations for lines of treatment are provided by
the scientific committee after data analysis and interpretation of the results
of a survey of 36 psychiatrist experts in the field of major depression and its
treatments.
RESULTS: The expert guidelines combine scientific evidence and expert
clinician’s opinion to produce recommendations for major depression with
comorbid anxiety disorders, personality disorders or substance use disorders and
in geriatric depression.
CONCLUSION: These guidelines provide direction addressing common clinical
dilemmas that arise in the pharmacologic treatment of major depression with
comorbid psychiatric conditions.
DOI: 10.1186/s12888-019-2025-7
PMCID: PMC6354367
PMID: 30700272 [Indexed for MEDLINE]
Conflict of interest statement: ETHICS APPROVAL AND CONSENT TO PARTICIPATE:
Written informed consents were obtained from participating medical experts.
CONSENT FOR PUBLICATION: Not Applicable. COMPETING INTERESTS: No financial
support was received for this study and there are no potential conflicts of
interest to declare. Regarding financial support unrelated to the present
article, we disclose that NA has benefited from financial support for
conferences and has been scientific responsible and experimenter for preclinical
studies from Servier laboratories. BA has perceived honoraria to communicate at
conferences from Laboratories AstraZeneca, Lundbeck and Janssen. VC has
benefited from honoraria and financial support for conferences from Laboratories
Otsuka, Novartis, Lundbeck, Servier, Janssen and has been experimenter for
studies from Janssen and Lilly.TC has benefited from honoraria and financial
support for conferences from Laboratories AstraZeneca, Janssen and Lundbeck and
has been experimenter for studies from Janssen. PC has benefited from honoraria
and financial support for conferences, training action and for participation in
experts groups from Servier and Janssen. OD has benefited from honoraria and
financial support for conferences from Lilly, AstraZeneca, Servier, Lundbeck and
Janssen. J-MD has benefited from honoraria for conferences from Lundbeck. WE has
benefited from honoraria and financial support for conferences, training action
and for participation in experts groups from Lundbeck, Janssen, and Otsuka. FH
has benefited from financial support for conferences, grant from BMS and
AstraZeneca, training grant from Servier and a research grant from « Fonds de
Recherche du Québec – Nature et Technologie (#200123) » and has been
experimenter for studies from EH has benefited from honoraria and financial
support for conferences, training action and for participation in experts groups
from AstraZeneca, BMS, Euthérapie Servier, Janssen, Livanova, Lundbeck, Otsuka
and has been experimenter for studies from Janssen. JH has benefited from
honoraria and financial support for conferences from Lundbeck, Servier has been
experimenter for studies from Janssen. CL has benefited from honoraria and
financial support for training action from Lundbeck. P-ML has benefited from
honoraria and financial support for conferences, training action and for
participation in experts groups from Janssen, EISAI, Lundbeck, Otsuka, Allergan.
FM has benefited from honoraria for conferences from Lundbeck, Otsuka. GV has
benefited from honoraria and financial support for conferences, training action
and for participation in experts groups from Janssen and Otsuka. AY has
benefited from honoraria and financial support for conferences from Lundbeck,
Janssen, AstraZeneca; for participation in experts groups from Lundbeck and has
participated in reseach studies from Lundbeck. PUBLISHER’S NOTE: Springer Nature
remains neutral with regard to jurisdictional claims in published maps and
institutional affiliations.